Recent News

• 03.05.2025 - TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
• 02.20.2025 - TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
• 02.13.2025 - TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
• 02.10.2025 - TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
• 02.05.2025 - TCBP to Implement ADS Ratio Change
• 02.05.2025 - TCBP to Implement ADS Ratio Change
• 01.15.2025 - TCBP Announces H5N1 Proof of Concept Studies Intention
• 01.13.2025 - TCBP to Present at Sequire Investor Summit 2025
• 01.13.2025 - TCBP to Present at Sequire Investor Summit 2025
• 01.06.2025 - TCBP Trading Continues Unabated on Nasdaq Stock Exchange

Recent Filings

• 02.10.2025 - EX-99.1 EX-99.1
• 02.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.08.2025 - EX-99.1 EX-99.1
• 01.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.31.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]